In the ever-evolving landscape of specialty pharmaceuticals, affordability and access remain front and center for patients, payers, and pharmacies alike. MedImpact Holdings Inc. is now poised to make a significant stride in this arena with the announcement of direct access to an unbranded biosimilar version of ustekinumab-aekn, a lower-cost alternative to the well-known reference drug, Stelara.
Breaking Down the Announcement
MedImpact’s new biosimilar will be distributed by Anda, affiliated with Teva Pharmaceuticals USA, Inc., and available for purchase from Birdi, Inc., MedImpact’s preferred partner. Most importantly, any licensed specialty pharmacy will have access to this product, potentially opening the door to wider market competition.
It is well known that a drug’s cost rises at each step in the supply chain. By adopting an unbranded strategy, MedImpact aims to bypass traditional markups and inefficiencies that inflate prices along the journey from manufacturer to patient. The program will provide specialty pharmacies with a new sourcing channel… not just MedImpact clients… more choice and control over their pharmacy benefit spending.
The model is also about transparency. Moving away from convoluted rebate structures and towards clear, upfront pricing gives payers and members access to true costs when the medication is dispensed.
Will this program start a sea change in the marketplace? MedImpact’s move is more than just another product launch… it’s a signal of changing tides in specialty pharmacy, where value, choice, and transparency are fast becoming the new standard. The availability date for the unbranded ustekinumab-aekn biosimilar is January 01, 2026.
MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US
CLICK HERE to read the full press release
